Preventing Hepatitis B in US Adults Through Vaccination

William Schaffner, Kristin L. Nichol, Arthur L. Reingold

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic hepatitis B virus (HBV) infection causes substantial morbidity, with up to 40% of infected individuals developing cirrhosis, hepatocellular carcinoma, or liver failure. Approximately 25% of individuals with chronic hepatitis B will die prematurely from these complications. Hepatitis B vaccines are safe and more than 90% effective in preventing infection in at-risk adults, yet only approximately 25% of US adults for whom vaccination is recommended by the Centers for Disease Control and Prevention are vaccinated. The rate of new HBV infections dropped substantially in the United States after the introduction and high uptake of hepatitis B vaccines in infants and children, and the burden of disease has shifted primarily to adults. There has been a resurgence of hepatitis B cases in US adults in recent years, with sharp increases in new cases noted in states highly impacted by the opioid epidemic. Improved hepatitis B vaccination coverage rates in US adults can help slow the rate of acute infections and reduce the reservoir of infection in US adults.

Original languageEnglish (US)
Pages (from-to)304-312
Number of pages9
JournalInfectious Diseases in Clinical Practice
Volume26
Issue number6
DOIs
StatePublished - Nov 1 2018

Keywords

  • HBV
  • chronic hepatitis
  • hepatitis B virus
  • vaccines

Fingerprint Dive into the research topics of 'Preventing Hepatitis B in US Adults Through Vaccination'. Together they form a unique fingerprint.

Cite this